TEVA catalysts
Catalysts and events linked to TEVA, newest first.
TEVA stock catalysts and risks
Latest published review: 2026-10-20
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| Teva Real-World Data Shows UZEDY Lowers Emergency Healthcare Utilization 2026-09-19 · Up | specialty brand revenue growth via commercial payer formulary placement | Real-world data showed UZEDY outperformed alternative long-acting injectables in continuity and reduced emergency costs. | Not recorded |
| Teva Real-World Data Shows UZEDY Superiority in Schizophrenia Continuity 2026-09-19 · Up | commercial formulary access expansion and specialty pharma revenue growth | Real-world study confirms treatment continuity and healthcare cost reduction for UZEDY. | Not recorded |
| Teva Highlights Real-World Data Demonstrating UZEDY Superiority in Treatment Continuity 2026-09-19 · Up | CNS specialty revenue growth via commercial payer adoption | Teva published real-world data showing UZEDY reduced emergency care and healthcare costs in schizophrenia. | Not recorded |
| Teva presents real-world data showing UZEDY treatment continuity advantage 2026-09-19 · Up | specialty pharmaceutical formulary adoption | Real-world study establishes treatment continuity superiority and healthcare cost reductions for UZEDY. | Not recorded |
| Teva real-world data demonstrates UZEDY reduces emergency care and medical costs 2026-09-19 · Up | specialty prescription volume growth via preferential formulary access | UZEDY showed superior treatment continuity and emergency care cost reduction. | Not recorded |
| Teva Real-World Study Shows UZEDY Outperforms Long-Acting Injectables 2026-09-19 · Up | specialty brand revenue growth via improved payer formulary placement | Real-world study confirms treatment continuity and healthcare cost reduction for UZEDY | Not recorded |
| Teva Clinical Evidence Highlights UZEDY Treatment Retention and Cost Reductions 2026-09-19 · Up | commercial formulary access expansion and specialty prescription volume growth | Real-world study showed UZEDY demonstrated superior treatment continuity and reduced emergency healthcare utilization. | Not recorded |
| Teva Launches EUR and USD Senior Notes Offering to Redeem 2028-2029 Debt 2026-09-07 · Up | debt maturity extension and interest expense reduction | Teva launched notes offering to redeem 6.750% 2028 notes and 7.875%/7.375% 2029 SLNs. | Not recorded |
Do these developments change your position?
Review TEVA alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-09-19Teva Real-World Data Shows UZEDY Superiority in Schizophrenia ContinuityTEVA
- 2026-09-19Teva real-world data demonstrates UZEDY reduces emergency care and medical costsTEVA
- 2026-09-19Teva real-world data demonstrates UZEDY reduces emergency care and medical costsTEVA
- 2026-09-19Teva Real-World Data Shows UZEDY Superiority in Schizophrenia ContinuityTEVA
- 2026-09-19Teva Clinical Evidence Highlights UZEDY Treatment Retention and Cost ReductionsTEVA
- 2026-09-19Teva Real-World Study Shows UZEDY Outperforms Long-Acting InjectablesTEVA
- 2026-09-19Teva presents real-world data showing UZEDY treatment continuity advantageTEVA
- 2026-09-19Teva Highlights Real-World Data Demonstrating UZEDY Superiority in Treatment ContinuityTEVA
- 2026-09-19Teva Highlights Real-World Data Demonstrating UZEDY Superiority in Treatment ContinuityTEVA
- 2026-09-19Teva Real-World Data Shows UZEDY Lowers Emergency Healthcare UtilizationTEVA
- 2026-09-19Teva Real-World Data Shows UZEDY Superiority in Schizophrenia ContinuityTEVA
- 2026-09-19Teva presents real-world data showing UZEDY treatment continuity advantageTEVA
- 2026-09-19Teva real-world data demonstrates UZEDY reduces emergency care and medical costsTEVA
- 2026-09-19Teva Real-World Study Shows UZEDY Outperforms Long-Acting InjectablesTEVA
- 2026-09-19Teva Clinical Evidence Highlights UZEDY Treatment Retention and Cost ReductionsTEVA
- 2026-09-07Teva Launches EUR and USD Senior Notes Offering to Redeem 2028-2029 DebtTEVA
- 2026-09-07Teva Launches EUR and USD Senior Notes Offering to Redeem 2028-2029 DebtTEVA
- 2026-09-07Teva Launches Multi-Currency Senior Notes to Refinance High-Coupon 2028-2029 DebtTEVA
- 2026-09-07Teva launches EUR and USD senior notes to refinance high-coupon 2028-2029 debtTEVA
- 2026-09-07Teva Launches EUR and USD Senior Notes Offering to Redeem 2028-2029 DebtTEVA
- 2026-09-07Teva Launches Multi-Currency Senior Notes to Refinance High-Coupon 2028-2029 DebtTEVA
- 2026-08-26Multiple System Atrophy Drug Pipeline Expands to 24 Clinical Candidates Across 22 FirmsIONS TEVA XBI-2.50%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.